{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Resistance&page=9", "query": { "condition": "Drug Resistance", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 520, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Resistance&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Resistance&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:57:09.143Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00091377", "title": "Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "phenoxodiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 65, "start_date": "2004-08", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091377" }, { "nct_id": "NCT07580183", "title": "Spatial Scene Recognition Memory in Epilepsy Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Focal Epilepsy", "Temporal Lobe Epilepsy", "Medically Refractory Epilepsy", "Memory Disorders", "Epilepsy Comorbidities", "Epilepsy Intractable", "Epilepsy Surgery", "Epilepsy, Temporal Lobe", "Memory Deficits", "Memory Disorder, Spatial", "Memory Dysfunction", "Spatial Perception" ], "interventions": [ { "name": "Virtual Tour Recognition Memory Task", "type": "BEHAVIORAL" }, { "name": "Intracranial EEG Recording with Research Electrodes (Aim III only)", "type": "DEVICE" }, { "name": "MRI Neuroimaging and Neuropsychological Assessment (Aim I)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE", "DIAGNOSTIC_TEST" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 620, "start_date": "2024-07-01", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 2, "location_summary": "Sacramento, California • Atlanta, Georgia", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07580183" }, { "nct_id": "NCT04296890", "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epithelial Ovarian Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab Soravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunoGen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 106, "start_date": "2020-07-23", "completion_date": "2022-11-16", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Duarte, California • Fresno, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04296890" }, { "nct_id": "NCT03799003", "title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1951", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2019-01-14", "completion_date": "2023-07-06", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 20, "location_summary": "Tucson, Arizona • Sacramento, California • Gainesville, Florida + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03799003" }, { "nct_id": "NCT07669168", "title": "Health Ahead Comparative Effectiveness Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Health Services Accessibility", "Rural Health", "Medically Underserved Area", "Preventive Health Services", "Patient Participation", "Health Behavior", "Aging", "Cardiovascular Diseases", "Metabolic Syndrome", "Cognitive Dysfunction", "Frailty", "Activities of Daily Living", "Health Related Quality of Life", "Health Equity", "Telemedicine" ], "interventions": [ { "name": "AI-Assisted Screening Interpretation (AI Reads)", "type": "BEHAVIORAL" }, { "name": "Human-Only Screening Interpretation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "William Brandenburg, MD", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000000, "start_date": "2026-06-09", "completion_date": "2099-12-31", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 1, "location_summary": "Boulder, Colorado", "locations": [ { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07669168" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT00118157", "title": "Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Positive", "Male Breast Carcinoma", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2005-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-12-04", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 2, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118157" }, { "nct_id": "NCT00035854", "title": "New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "Zyvox® / Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 13, "start_date": "2002-02", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2009-08-14", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 21, "location_summary": "Long Beach, California • Los Angeles, California • Hartford, Connecticut + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035854" }, { "nct_id": "NCT02607228", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castrate-Resistant Prostate Cancer" ], "interventions": [ { "name": "Alobresib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2015-12-08", "completion_date": "2019-09-03", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 4, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607228" }, { "nct_id": "NCT03644966", "title": "Probiotics and Multi-Drug Resistant Urinary Tract Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Tract Infections", "Recurrent UTI", "Antibiotic Resistant Infection" ], "interventions": [ { "name": "Bifidobacterium infantis", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Antibiotics", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 25, "start_date": "2018-07-05", "completion_date": "2022-12-15", "has_results": false, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-11-15T11:57:09.143Z", "location_count": 1, "location_summary": "Jefferson, Louisiana", "locations": [ { "city": "Jefferson", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644966" } ] }